Audit: QRS - Rose Oil for Health & Longevity
Audit conducted on 06/10/2026 04:17 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 85 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol, time-to-effect, benefit, risk, gate and monitoring content traces to ER lines 145–396 and the Conclusion (line 411); “topical” for ER “skin” is a route-terminology equivalent. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “(theoretical)” retained on every interaction; “(general caution; no threshold has been published)” retained; “No established target” retained in Monitoring. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Monitor/caution/avoid categories match ER lines 286–295; contraindications match ER lines 299–302. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Each item sits under its ER category. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, citations or brands; scale names (Pittsburgh, Spielberger) are from the ER Monitoring table. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | None introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-weighted tone mirrors the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms (ALT, AST, SNRIs) are expanded. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | At-A-Glance closes with “For risk-aware adults…”. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Routes given as “inhaled”, “topical”, “oral”. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed labels unchanged. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All template spans present; marker_# and qualitative_item_# expanded to numbered instances. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against template shows only variable content and metadata changed. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the empty High/Medium risk tiers are governed by 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels and interaction labels match ER bold labels (lines 286–295, 323–325). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emojis. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed (drug example lists trimmed, mitigation clauses dropped). |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration is quoted (contains a colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.10.1 |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-1006-0357 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Opus |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Opus 5.5 |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 10/06/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | “Rose oil, an essential oil from damask rose petals, is inhaled mostly to ease stress, pain and poor sleep.” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | ER lines 40, 92, 411. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | ER lines 297–302. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All four populations listed. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Citations and the pregnancy study details stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(general caution; no threshold has been published)” preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | No ranking notation in the ER contraindications. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated, consistent with the ER. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | ER lines 286–295. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Nine interactions listed; the “no adverse interaction found” pain-reliever entry is correctly omitted. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanisms, citations and mitigations stripped; the em-dash in “Other interventions — topical medications and broken skin” is part of the ER bold label, not a trailing clause. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists trimmed but retained; “(theoretical)” retained. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | No ranking notation in the ER interactions. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated, consistent with the ER. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | ER Therapeutic Protocol, lines 323–325. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Anxiety, sleep and pain protocols correspond to the three High-tier benefits. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides more than three aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | ER line 359. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Sleep (largest pooled SMD) and anxiety/pain (High tier) precede sexual function (Medium tier). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three aspects available. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | ER lines 145–217. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers have items. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | ER lines 234–270. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high and risks_medium set to display: none (lines 573–574). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | ER lines 376–388. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven table biomarkers listed. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Matches ER line 378. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | ER lines 390–396. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five qualitative markers listed verbatim. |
Issues 06/10/2026 04:17
Pass rate 100.00%. No issues found.
Issues 06/10/2026 04:14
- 2.15 — Lay route-of-administration phrasing: At-a-Glance (line 433) says “skin or oral use has not reliably eased pain” and marker_4_why (line 637) says “stops skin use”, using the lay “skin use” instead of the formal “topical use”.
- 8.4 — Rationale kept in contraindication: stop_items (line 543) “Pregnant or breastfeeding women, for oral use (no safety data)” retains the explanatory rationale “(no safety data)”, which is not a time window, severity, threshold or staging qualifier.
- 14.2 — AST biomarker omitted: The ER Monitoring table (ER line 386) calls for AST (aspartate aminotransferase) to be paired with ALT, but the QRS Monitoring table (lines 641-650) lists only ALT.
Fixes 06/10/2026 04:14
- 2.15 — Formal route-of-administration term: Changed “skin or oral use” to “topical or oral use” in At-a-Glance and “stops skin use” to “stops topical use” in marker_4_why.
- 8.4 — Removed contraindication rationale: Stripped “(no safety data)” from the pregnancy/breastfeeding contraindication, leaving “Pregnant or breastfeeding women, for oral use”.
- 14.2 — Added AST to liver marker: Extended marker_5_name to “ALT (alanine aminotransferase, a liver enzyme), paired with AST (aspartate aminotransferase)”, as the ER Monitoring table specifies.
Issues 06/10/2026 04:12
- 2.15 — Colloquial “faked” in lede: At a Glance (line 433) says “many products are diluted or faked”; “faked” is consumer-grade language where the ER uses “adulteration” / “diluted or replaced”.
Fixes 06/10/2026 04:12
- 2.15 — Colloquial “faked” replaced: Changed “many products are diluted or faked” to “many products are diluted or substituted” in At a Glance (word count stays at 70).
Issues 06/10/2026 04:07
- 4.5 — Key Interactions not condensed: The Key Interactions gate (lines 552-563) carries all 10 ER bullets with full example-drug lists, including the non-interaction item “Over-the-counter pain relievers … no adverse interaction found” (line 558), so the section is not condensed to the one-page budget.
Fixes 06/10/2026 04:07
- 4.5 — Key Interactions condensed: Removed the non-interaction item “Over-the-counter pain relievers (diclofenac, ibuprofen): no adverse interaction found” and trimmed the example-drug lists of the remaining items to one to three examples each, keeping ER labels and “(theoretical)” qualifiers.
Issues 06/10/2026 04:04
- 2.13 / 7.2 — Missing audience bottom line: At a Glance (line 433) omits the ER Conclusion’s net takeaway for risk-aware adults (“authentic rose oil inhaled briefly pairs modest, short-lived benefit with small risk”, ER line 411), so the lede has no execution-oriented risk/benefit verdict.
- 7.5 — Technical term in lede: “many products are adulterated” (line 433) uses a word non-specialists would not use unprompted; plain wording (e.g., “diluted or faked”) is needed.
Fixes 06/10/2026 04:04
- 2.13 / 7.2 — Added audience bottom line: Appended the ER Conclusion’s net takeaway to At a Glance (“For risk-aware adults, briefly inhaled authentic oil offers modest benefit at small risk”) and tightened earlier wording to stay within 70 words.
- 7.5 — Replaced technical term: Changed “many products are adulterated” to “many products are diluted or faked” in At a Glance.
Issues 06/10/2026 04:00
- 4.2 / 4.3 — Interaction labels not verbatim: “SSRIs and SNRIs” (line 554) drops the ER label’s “(serotonin-norepinephrine reuptake inhibitors)”, and “Other interventions (topical medications and broken skin)” (line 562) rewrites the ER label “Other interventions — topical medications and broken skin:”.
- 4.5 — Exceeds one A4 page: Ten multi-line interaction items with trailing clauses (lines 553-562), Time-to-effect sub-lines that merely restate their values (lines 489, 500, 511), long protocol subs and a long cadence line (line 678) push the sheet well beyond one A4 page.
- 9.4 — Trailing clauses in interactions: Caution items keep effect/rationale clauses after the action level, e.g. “; additive drowsiness” (lines 553, 557, 559, 561), “; small additive drop in blood pressure” (556) and “; cumulative skin-sensitizer load” (560).
Fixes 06/10/2026 04:00
- 4.2 / 4.3 — Interaction labels restored verbatim: Changed “SSRIs and SNRIs” to the ER label “SSRIs and SNRIs (serotonin-norepinephrine reuptake inhibitors)” and “Other interventions (topical medications and broken skin)” to “Other interventions — topical medications and broken skin:”.
- 9.4 — Trailing interaction clauses stripped: Removed the effect/rationale clauses after the action level (e.g., “; additive drowsiness”, “; cumulative skin-sensitizer load”), keeping drug class, examples, action level and “(theoretical)”.
- 4.5 — Condensed for one page: Besides the shorter interaction items, replaced the redundant Time-to-effect sub-lines with short route notes (“With nightly inhalation”, “After inhalation”, “With daily oral drops”) and tightened the monitoring cadence line.